NCT05633628 Periodic Continuous Glucose Monitoring in Patients With Type 2 Diabetes
| NCT ID | NCT05633628 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sophiahemmet University |
| Condition | Type 2 Diabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-02-01 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2023-02-01 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this randomised controlled trial is to investigate the effectiveness of periodic CGM (continuous glucose monitoring) to support a person-centered approach versus self-monitoring of blood glucose (SMBG) in adults with type 2 diabetes on glucose control and patient reported outcomes.
Eligibility Criteria
Inclusion Criteria: * Adults aged 18-80 years * Type 2 diabetes with a duration of \> 6 months * HbA1c 45-70 mmol/mol * Have a smartphone * Experience of self-monitoring of blood glucose prior to the study start Exclusion Criteria: * Prandial insulin * Pregnancy or planning pregnancy during the study * Breastfeeding * Renal disease with estimated glomerular filtration rate (eGFR) \<45 mL/ min/1.73 m2 * Active malignancy or under investigation for malignancy * Severe visual impairment * Severe skin allergy that inhibits the use of a continuous glucose monitoring device * Glucocorticoids (systemic) * Planned or currently using weight reduction medications, programs, or surgery * Cognitively or psychologically unable to participate and read instructions * Enrolled in other clinical trials * Eating disorders
Contact & Investigator
Unn-Britt Johansson
PRINCIPAL INVESTIGATOR
Sophiahemmet University
Frequently Asked Questions
Who can join the NCT05633628 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Type 2 Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05633628 currently recruiting?
Yes, NCT05633628 is actively recruiting participants. Contact the research team at unn-britt.johansson@shh.se for enrollment information.
Where is the NCT05633628 trial being conducted?
This trial is being conducted at Stockholm, Sweden.
Who is sponsoring the NCT05633628 clinical trial?
NCT05633628 is sponsored by Sophiahemmet University. The principal investigator is Unn-Britt Johansson at Sophiahemmet University. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.